Stocks · News reference

Evolus Announces Expanded Symatese Agreement For Exclusive Estyme HA Gel Rights In Canada, Australia, New Zealand; Terms Not Disclosed

Aug 4, 2026, 12:35 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 1, 2026, 7:59 AMBenzinga Newsdesk
Reported Earlier, Telix Names David Gill Board Chair As Mark Nelson Steps Down From Interim Role
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix" or the "Company") today announces that David Gill has been appointed Chair of the Board, effective immediately.Mr. Gill joined Telix as a
EOLS TLX
BenzingaAug 25, 2026, 11:56 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $13 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $13 price target.
EOLS
BenzingaAug 5, 2026, 8:28 PMBenzinga Newsdesk
Evolus Q2 EPS $(0.12), Sales $84.084M Beat $81.603M Estimate
Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 0 percent. This is a 47.83 percent increase over losses of $(0.23) per share from the same
EOLS
BenzingaAug 5, 2026, 8:09 PMBenzinga Newsdesk
Evolus Raises FY2026 Sales Guidance from $327.000M-$337.000M to $330.000M-$337.000M vs $330.445M Est
Evolus (NASDAQ:EOLS) raises FY2026 sales outlook from $327.000 million-$337.000 million to $330.000 million-$337.000 million vs $330.445 million estimate.
EOLS